Lamivudine therapy for hepatitis B in renal transplantation
Braz. j. med. biol. res
;
35(2): 199-203, Feb. 2002. tab
Article
in English
| LILACS
| ID: lil-303547
RESUMO
Antiviral therapies are associated with an increased risk of acute rejection in transplant patients. The aim of the present study was to evaluate the efficacy and safety of lamivudine therapy for hepatitis B virus (HBV) infection in renal transplant patients. Six patients were included in this study. They received 150 mg/day of lamivudine during a follow-up period of 24 months. The laboratory tests monitored were HBV DNA, HBsAg, HBeAg, ALT, gamma-GT, serum creatinine and blood cyclosporine levels. The HBV DNA became undetectable in four patients as early as in the third month of treatment. After six months, the viral load was also negative in the other two patients, and remained so until 18 months of follow-up. The medication was well tolerated with no major side effects. Lamivudine was safe and effective in blocking HBV replication in renal transplant patients without any apparent increase in the risk of graft failure for the 24-month period of study
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Kidney Transplantation
/
Reverse Transcriptase Inhibitors
/
Lamivudine
/
Graft Rejection
/
Hepatitis B
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Braz. j. med. biol. res
Journal subject:
Biology
/
Medicine
Year:
2002
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Hospital Beneficência Portuguesa de Säo Paulo/BR
Similar
MEDLINE
...
LILACS
LIS